Is there scientific evidence that the true rife machine works?

Scientific research regarding Rife machine efficacy is limited, but according to Dr. Rife, the inventor of the Rife machine, “The first clinical work on cancer was completed under the supervision of Milbank Johnson, M.D., which was set up under a special medical research committee of the University of Southern California. Sixteen cases were treated at the clinic for many types of malignancy. After just three months, 14 of these so-called hopeless cases were signed off as clinically cured by a staff of medical doctors and Alvin G. Ford, M. D., pathologist for the group.”

Also, a 1994 review by the American Cancer Society on the Rife noted that “once the cancer causing bugs were identified by the Rife machine, it would generate radio frequencies of exactly the same vibratory rates as the bacteria and destroy them”.

In addition to this, researchers have studied different types of cancer cells to see if therapy using electromagnetic waves had any effect. One study (2012) showed that the growth of hepatocellular carcinoma (HCC), the most common type of liver cancer, as well as breast cancer, were “significantly decreased” when exposed to cancer-specific frequencies without affecting healthy cells.

Another study using breast cancer cells showed considerable changes in cancerous tissues treated by electromagnetic fields, including decreased tumor mass, cancer cell death, and reduction in blood vessels feeding cancer.

Other research used electromagnetic fields to treat breast and colon cancer cells. The results clearly showed the disintegration of cancer cells compared to untreated cells, resulting in early cell death in just three days. More research (2017) shows that low-frequency magnetic fields can inhibit lung cancer cell growth by killing cancer cells.

Ultimately, research indicates that treating cancer with intra-buccally administered  electromagnetic fields is generally safe and well-tolerated in patients and may even lead to long-lasting therapeutic responses in patients with advanced cancer.